Azacitidine (5-Azacytidine)

Name: Azacitidine (5-Azacytidine)
Brand: Selleck Chemicals
SKU: S1782
Rating: 5 (56 reviews)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza, CC-486

56 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza, CC-486) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Selleck's Azacitidine (5-Azacytidine) has been cited by 56 publications

Cancer Cell, 2019, 35(2):333-335

PubMed: 30753831 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):724-740.e4

PubMed: 30423294 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31382-X

PubMed: 29249359 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

J Hematol Oncol, 2021, 14(1):70

PubMed: 33902674 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):570

PubMed: 34108444 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):90

PubMed: 33941774 ( click the link to review the publication )

Sci Rep, 2021, 11(1):6270

PubMed: 33737539 ( click the link to review the publication )

Sci Rep, 2021, 11(1):5715

PubMed: 33707624 ( click the link to review the publication )

Blood Adv, 2021, 5(10):2467-2480

PubMed: 33999145 ( click the link to review the publication )

Transgenic Res, 2021, 30(1):63-76

PubMed: 33394315 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Front Immunol, 2020, 11:594540

PubMed: 33569051 ( click the link to review the publication )

Neoplasia, 2020, 22(3):142-153

PubMed: 32062068 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Technol Cancer Res Treat, 2020,

PubMed: 32715976 ( click the link to review the publication )

Target Oncol, 2020, 15(2):231-240

PubMed: 32222953 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )
Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Clin Transl Oncol, 2020, 10.1007/s12094-020-02464-x

PubMed: 32737836 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

J Biochem Mol Toxicol, 2020, e22621

PubMed: 32894642 ( click the link to review the publication )

Stem Cell Reports, 2020, 15(2):408-423

PubMed: 32735821 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128571

PubMed: 31437130 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Environ Toxicol, 2019, 10.1002/tox.22873

PubMed: 31724259 ( click the link to review the publication )

J Pharmacol Sci, 2019, 140(2):187-192

PubMed: 31345653 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

Med Sci Monit, 2019, 25:9426-9434

PubMed: 31822650 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30412053 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 5;37(1):305

PubMed: 30518424 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(5)E1414

PubMed: 29747401 ( click the link to review the publication )

Int J Mol Sci, 2018, 20(1)

PubMed: 30577584 ( click the link to review the publication )
Mol Cancer Res, 2017, 15(9):1243-1254

PubMed: 28522693 ( click the link to review the publication )

Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Sci Transl Med, 2015, 7(290):290ra89

PubMed: 26041706 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	NYf5T\|dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW4NE4yNTVyIN88US=>	M1fYXFEzNTd{IHi=		NGe4XHZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NFXxW4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzN\|I1Pid-Mk[xN\|MzPDZ:L3G+
Jurkat	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKwMlEuPTBizszN	MXmxNk04OiCq		Ml3jbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M{nY[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN\|I1PjxxYU6=
CA46	NEn6UXdHfW6ldHnvckBCe3OjeR?=	NVPOcJVROjEEoNM1US=>	NH\j[201QCCq		MWXpcoNz\WG\|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25?	MnvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Raji	NVT5OJJOTnWwY4Tpc44hSXO\|YYm=	NFPuR4IyPcLiwsXN	MXe0PEBp		M2HmeYlv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|M{K0Okc,OjZzM{OyOFY9N2F-
Jurkat	NYPUfVZpTnWwY4Tpc44hSXO\|YYm=	M1rOT\|MvPcLiwsXN	M2ToclQ5KGh?		MX\pcoNz\WG\|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25?	M1W1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN\|I1PjxxYU6=
MDA-MB-231	NHrw[ZBHfW6ldHnvckBCe3OjeR?=	MXSxM\|IvPS93IN88US=>	NWO1UYltPDhiaB?=		NIH6VZdl\WO{ZXHz[ZMhfGinIGDUVG4yOiCneIDy[ZN{cW:wIHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB3wrFOwG0hPDkEoHi=	NWn3b2Y1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVczOjlpPkK1PFE4OjJ7PD;hQi=>
MDA-MB-231	Mkf6SpVv[3Srb36gRZN{[Xl?	MnHJNU8zNjVxNTFOwG0>	M1Gw[FQ5KGh?		NUTPR\|BUcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gSU1k[WSqZYLpckBuWk6DIHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB{LkZCpO69VW[xcjC0POKhcA>?	M1LJW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG3NlI6Lz5{NUixO\|IzQTxxYU6=
MDA-MB-231	MVPGeY5kfGmxbjDBd5NigQ>?	MV:xM\|IvPS93IN88US=>	MYqyOE81QCCq		M3vGfolv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=>	NVTkbHJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVczOjlpPkK1PFE4OjJ7PD;hQi=>
MCF-7	NXqxWJNDTnWwY4Tpc44hSXO\|YYm=	MWixM\|IvPS93IN88US=>	M4rBOFI1NzR6IHi=		MWLpcoNz\WG\|ZYOgVGFTWCClbHXheoFo\cLi	NUDzXXZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVczOjlpPkK1PFE4OjJ7PD;hQi=>
MDA-MB-231	MX\GeY5kfGmxbjDBd5NigQ>?	MkTiNU8zNjVxNTFOwG0>	NXnodZQ4OjRxNEigbC=>		NG\NNZhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhdWmUTlGtNVI1KGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2KM7:TR?=	NF6yU4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixO\|IzQSd-MkW4NVczOjl:L3G+
A498	M2nNW2Z2dmO2aX;uJGF{e2G7	NGHwOosyOCEEtV2=	NW\PVGpxPzJiaB?=		MX\pcoR2[2W\|IITo[UBCTEGPVGOxPEBo\W6nIHX4dJJme3Orb36=	NIXsTI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2PVA5Pid-MkW1OlkxQDZ:L3G+
CaKI-2	Ml75SpVv[3Srb36gRZN{[Xl?	MVexNEDDvU1?	NHe1THU4OiCq		NF3GbIJqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	NUWzd5A5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlkxQDZpPkK1OVY6ODh4PD;hQi=>
Ketr-3	NH7ZSIVHfW6ldHnvckBCe3OjeR?=	Mm\JNVAhyrWP	M3XPeFczKGh?		Mme2bY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO\|aX;u	Mn3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkmwPFYoRjJ3NU[5NFg3RC:jPh?=
A253	M1;nV2Z2dmO2aX;uJGF{e2G7	NV;SOmNKOTBiwsXN	Mmq5NE01KGR?		NYPGblBHcW6lcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WsLiYX\0[ZIhOjRiaB?=	NFfCNmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4OVU{Pid-MkW0PFU2OzZ:L3G+
A253	MWDGeY5kfGmxbjDBd5NigQ>?	MVixNEDDvU1?	MWq3NkBp		M{XRTolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjD0bIUhVTOUIHnuJIJwfGhibXXtZpJidmViYX7kJIN6fG:\|b3zpZ{BxemWyYYLheIlwdnN?	M1\FeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi1OVM3Lz5{NUS4OVU{PjxxYU6=
A253	NYHRSodlTnWwY4Tpc44hSXO\|YYm=	NH\w[20yOCEEtV2=	Mnr4NE01KGR?		NWTuXWR2emWmdXPld{B1cGViNT3t[ZRpgWyleYTvd4lv\SClb370[Y51	MkLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW1N\|YoRjJ3NEi1OVM3RC:jPh?=
PC3	Mny4SpVv[3Srb36gRZN{[Xl?	NX3UVnVrOC5{IN88UeKh	MlfoOEBl		NVW2OpZKcW6lcnXhd4V{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gTWdHSlB5LDDTSnJROSCjbnSgV2xEPkFzNTDjc41jcW6nZDD3bZRpKEeVS{GyOi=>	NYPMemJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{PDBpPkK1OFc4OzRyPD;hQi=>
MCF7	MXjGeY5kfGmxbjDBd5NigQ>?	M3vUc\|AvOyEQvF5CpC=>	NGW0UnU1KGR?		M4H4d4lv[3KnYYPld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyxiU1\SVFEh[W6mIGPMR\|ZCOTViY3;tZolv\WRid3n0bEBIW0tzMk[=	NULpPG5GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{PDBpPkK1OFc4OzRyPD;hQi=>
PC3	M1PZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGry[nYxNjJizszNxsA>	NX3FcY1JPCCm		MmDO[IVkemWjc3XzJJRp\SClZXzsJIdzd3e2aDD0c{AzOC5\|JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=>	NYG3Z5FWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{PDBpPkK1OFc4OzRyPD;hQi=>
MCF7	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\ESXcxNjNizszNxsA>	MWS0JIQ>		MU\k[YNz\WG\|ZYOgeIhmKGOnbHyg[5Jwf3SqIEK0MlgmKGOxbXLpcoVlKHerdHigS3NMOTJ4	NFrmcGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|M1OCd-MkW0O\|c{PDB:L3G+
BGC-823	NHv5c2NHfW6ldHnvckBCe3OjeR?=	MnrLOeKh\|ryP	MXO3NkBp		NUWxZmVi\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5NUezN{c,OjV2N{W3N\|M9N2F-
MKN28	MkS3SpVv[3Srb36gRZN{[Xl?	MYS1xsDPxE1?	NV6yW4dKPzJiaB?=		MmTK[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=>	Mm\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N\|MoRjJ3NEe1O\|M{RC:jPh?=
SGC-7901	NELL[41HfW6ldHnvckBCe3OjeR?=	NEnaeHE2yqEQvF2=	MmK4O\|IhcA>?		M4H1eIRm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk>	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N\|MoRjJ3NEe1O\|M{RC:jPh?=
MKN45	MXnGeY5kfGmxbjDBd5NigQ>?	NGPCVYM2yqEQvF2=	M2\XfFczKGh?		Mljw[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=>	NVG3VZZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|U4OzNpPkK1OFc2PzN\|PD;hQi=>
BGC-823	NFLNW4ZHfW6ldHnvckBCe3OjeR?=	MlezOeKh\|ryP	NIHaWJE4OiCq		NGi3VlBl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDQVmwuOyC\|aXfubYZq[2GwdHz5	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5NUezN{c,OjV2N{W3N\|M9N2F-
MKN28	NW\HPJBvTnWwY4Tpc44hSXO\|YYm=	M3zNZ\|XDqM7:TR?=	M{fyZVczKGh?		M3S4eIRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm=	NI\Iboo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3OVc{Oyd-MkW0O\|U4OzN:L3G+
SGC-7901	MVTGeY5kfGmxbjDBd5NigQ>?	NVvod4xnPcLizszN	NWXD[oc6PzJiaB?=		NE\EblNl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDQVmwuOyC\|aXfubYZq[2GwdHz5	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5NUezN{c,OjV2N{W3N\|M9N2F-
MKN45	MkDVSpVv[3Srb36gRZN{[Xl?	MorNOeKh\|ryP	MYW3NkBp		Mon0[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?=	M4XucFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe1O\|M{Lz5{NUS3OVc{OzxxYU6=
HREC	Ml3TSpVv[3Srb36gRZN{[Xl?	MWC1M\|ExyqEQvF2=	Mn3POFghcA>?		MonUbY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV\|NUK3OFc9N2F-
HRPE	NXPFOXhzTnWwY4Tpc44hSXO\|YYm=	MVm1M\|ExyqEQvF2=	NH;TTHQ1QCCq		MomybY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3m4UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{WyO\|Q4Lz5{NUO1Nlc1PzxxYU6=
HREC	NWjpboEyTnWwY4Tpc44hSXO\|YYm=	NEDPcmM2NzFywrFOwG0>	NYHjV5ZrPDhiaB?=		MVnkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLQ1HNMVEhMG6xdDDwdo91\WmwIHzleoVtKGmwIFjSVGUh[2WubIOpMEBKVC1zzsKg[I9{\S2mZYDlcoRmdnSueR?=	M4f5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{WyO\|Q4Lz5{NUO1Nlc1PzxxYU6=
HRPE	M1S3e2Z2dmO2aX;uJGF{e2G7	NGrqdII2NzFywrFOwG0>	NYnZN2JSPDhiaB?=		NVLJ[4dz\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWwuOc7{LDDhcoQhVU2SMjDkc5NmNWSncHXu[IVvfGy7	NX\id2VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOVI4PDdpPkK1N\|UzPzR5PD;hQi=>
MSCs	MljqSpVv[3Srb36gRZN{[Xl?	M2nHWlExKM7:TR?=	NV\OPVR6OjRiaB?=		MonZdJJwdW:2ZYOgeIhmKGOxbX3peI1mdnRib3[gUXNEeyC2bzDtfY9k[XKmaXHsJIRq\m[ncnXueIlifGmxbh?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3MUO5OUc,OjV\|NUGzPVU9N2F-
HL-60	M2qxWGZ2dmO2aX;uJGF{e2G7	NH;SfnA2KM7:TR?=	NVXDOI5bPzJiaB?=	M2rWXGROW09?	NG\ISpJ{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO\|aX;u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNzOUC0PUc,OjV\|MUmwOFk9N2F-
MV4-11	MknLSpVv[3Srb36gRZN{[Xl?	MnTNOUDPxE1?	M{TzTVczKGh?	NVmzZo5FTE2VTx?=	NH7aT\|N{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO\|aX;u	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNzOUC0PUc,OjV\|MUmwOFk9N2F-
A2780	NYrldlRITnWwY4Tpc44hSXO\|YYm=	MUm1JOK2VcLi	NFTqTmU4KGR?		MoPKbY5kemWjc3XzJGRPSSCvZYTofYxifGmxbjDs[ZZmdA>?	Mli2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
CP70	NGjsPGdHfW6ldHnvckBCe3OjeR?=	NWDuSlhTPSEEtV5CpC=>	NXjJUpFnPyCm		NU[zPJNncW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?=	MnW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
A2780	M2HMXGZ2dmO2aX;uJGF{e2G7	NFz0S3A2KML3TdMg	MVK3JIQ>		NHzkXWt4\WGtZX7zJJRp\SCuZY\lcEBw\iCvZYTofYxifGmxbh?=	NGPRfWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5PVY6PCd-MkWyPVk3QTR:L3G+
CP70	MoDjSpVv[3Srb36gRZN{[Xl?	M{H5VVUhyrWPwrC=	MVO3JIQ>		MlTHe4Vic2WwczD0bIUhdGW4ZXygc4YhdWW2aInsZZRqd25?	Mm\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
OCM3	NHjtfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrvN5R[OC53L{GvNkDPxE1?	M4\HS\|ch\A>?	MUPEUXNQ	MmSwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NYXwZ49nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
92.1	NUjZcGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfWNmJDOC53L{GvNkDPxE1?	MVm3JIQ>	M1S0OGROW09?	MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M2e5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM1	M2r1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXxNE42NzFxMjFOwG0>	M{Pqclch\A>?	NEjVe4FFVVOR	Mon3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NUD4co1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OMM1	NYnVZYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfCTYQxNjVxMT:yJO69VQ>?	MoPwO{Bl	M2nmSmROW09?	NEXTPZpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NGf2VWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
Mel 285	NIrzS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuwMlUwOS9{IN88US=>	NGjKU4E4KGR?	MkTXSG1UVw>?	NYTOVZd2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M3T6VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
Mel 290	M{\GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7Dd24xNjVxMT:yJO69VQ>?	NX3oNmZFPyCm	M4HPNmROW09?	MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NVvoeJk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OCM3	MoDGSpVv[3Srb36gRZN{[Xl?	MUCwMlUwOSEQvF2=	M2SwWVQ5KGh?	MoXkSG1UVw>?	NWi0NXd1\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	NVjGfoVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
92.1	M3faN2Z2dmO2aX;uJGF{e2G7	NIqwXoExNjVxMTFOwG0>	MUi0PEBp	MoLsSG1UVw>?	MmfH[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	M4[4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM1	MWfGeY5kfGmxbjDBd5NigQ>?	M133NlAvPS9zIN88US=>	NXTEWYxjPDhiaB?=	M2TRbWROW09?	NGrsc5dl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7	M4G0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OMM1	NVvFb4p7TnWwY4Tpc44hSXO\|YYm=	NXvIT4pQOC53L{Gg{txO	M3P1bVQ5KGh?	MVnEUXNQ	MUPk[YNz\WG\|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6	NV;QNXlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
Mel 285	NVrMT5RlTnWwY4Tpc44hSXO\|YYm=	MX[wMlUwOSEQvF2=	NFWxcnY1QCCq	NUfjWpdsTE2VTx?=	M3fOToRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	NF\t[ZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
Mel 290	NELhTG1HfW6ldHnvckBCe3OjeR?=	M{m4U\|AvPS9zIN88US=>	M1q0NlQ5KGh?	MXfEUXNQ	NUn2bGdM\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
OCM3	NGG3WFNHfW6ldHnvckBCe3OjeR?=	NF7hT\|cxNjVxMTFOwG0>	M3XxOVQ5KGh?	NIfWZVRFVVOR	NHPWb3Zl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
Mel 290	MV;GeY5kfGmxbjDBd5NigQ>?	NGW3OoMxNjVxMTFOwG0>	NWC5W5NWPDhiaB?=	NX\pcZFXTE2VTx?=	MlHV[IVkemWjc3XzJIlvfmG\|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=>	MnvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OMM1	NEHnU5pHfW6ldHnvckBCe3OjeR?=	NI\hN\|YxNjVxMTFOwG0>	NGjsN5U1QCCq	NXvI[2ppTE2VTx?=	NV[3VoxU\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>?	NV7VRYxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OCM1	Mk\sR4VtdCCYaXHibYxqfHliQYPzZZk>	M3zOXFAvPS9zIN88US=>	MmDsOUBl	M4\MbWROW09?	NV\JSGdx\GWlcnXhd4V{KHKjZHnheIlwdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIlvcGmkaYTpc44>	NHjC[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
92.1	Ml7jR4VtdCCYaXHibYxqfHliQYPzZZk>	MlThNE42NzFizszN	NIjFfFE2KGR?	MULEUXNQ	MYXk[YNz\WG\|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?=	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1	NHfoWo5HfW6ldHnvckBCe3OjeR?=	NVy0UVlNOC53L{Gg{txO	NFvjNJM1QCCq	M3rIfGROW09?	NVXpXnRK[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=>	MlnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM3	M2jafGZ2dmO2aX;uJGF{e2G7	NYnBflBYOC53L{Gg{txO	Mnq5OFghcA>?	MX;EUXNQ	MoHrZ4F2e2W\|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
92.1	NXr6d4pkTnWwY4Tpc44hSXO\|YYm=	Mn\CNE42NzFizszN	MnzpOFghcA>?	NV\JbXNsTE2VTx?=	MULjZZV{\XNiZ3zvZoFtKESQQTDofZBwdWW2aInsZZRqd25iYYSgUE0yKHKncHXheEBtd2Or	M4rj[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
IMR32	NWrM[3FiTnWwY4Tpc44hSXO\|YYm=	Mk\oN{DPxE1?	MlzyO\|IhcA>?	MmLjSG1UVw>?	M1vzSIlv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNEi1NEc,OjVzMES4OVA9N2F-
IMR5-75	NEjmeodHfW6ldHnvckBCe3OjeR?=	NUfBc3RKOyEQvF2=	NFrGSXg4OiCq	MVLEUXNQ	NV3JNGRHcW6mdXPld:KheDF7LVnOT\|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6	NUPrc3JkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFQ5PTBpPkK1NVA1QDVyPD;hQi=>
Be(2)-C	MlLxSpVv[3Srb36gRZN{[Xl?	NEXWe5Q{KM7:TR?=	MWe3NkBp	NUPZeGZ1TE2VTx?=	M33lR4lv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=>	M3;ZWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC0PFUxLz5{NUGwOFg2ODxxYU6=
Bxpc-3	NFrLUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHmZlhTPS9zMDFOwG0>	M4\KfFI1NzR6L{eyJIg>		MmDDbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhSniyYz2zJINmdGy\|IHnuJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XK\|	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUezNUc,OjVyNkG3N\|E9N2F-
Bxpc-3	M1HG[WFxd3C2b4Ppd{BCe3OjeR?=	NFmycY42NzFyIN88US=>	MUmyOE81QC95MjDo		MVjpcoR2[2W\|IHHwc5B1d3OrczDpckB1cW2nLTDhcoQh[2:wY3XycpRz[XSrb36gcYFvdmW{cx?=	NYDyTJBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlE4OzFpPkK1NFYyPzNzPD;hQi=>
Bxpc-3	MWTGeY5kfGmxbjDBd5NigQ>?	M2PQ[VUwOTBizszN	M13n[FI1NzR6L{eyJIg>		NEH3W5Vl\WO{ZXHz[ZMh\|rJvY3H0[Y5qdiCneIDy[ZN{cW:wIHHmeIVzKDJ2IHi=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUezNUc,OjVyNkG3N\|E9N2F-
Bxpc-3	NETKe3VHfW6ldHnvckBCe3OjeR?=	NHv2S402NzFyIN88US=>	M3G1cVI1NzR6L{eyJIg>		NG\KNJVl\WO{ZXHz[ZMh[3mlbHnuSFEh\XiycnXzd4lwdiCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOTBizszN	NYfKNGMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlE4OzFpPkK1NFYyPzNzPD;hQi=>
Bxpc-3	M37DbmZ2dmO2aX;uJGF{e2G7	NWj6eld5PS9zMDFOwG0>	MonxNlQwPDhxN{KgbC=>		MnvD[I94di2{ZXf1cIF1\VNiYz3tfYMhdVKQQTDlfJBz\XO\|aX;uJIlvKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYLz	M16yZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xO\|MyLz5{NUC2NVc{OTxxYU6=
HL-60	NXT0UHJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDwTGsyNjBizszN	MnTmOFghcA>?		NH76dmR{cWewaX\pZ4FvfGy7IHnubIljcXS\|IFjMMVYxKGOnbHyg[5Jwf3SqwrC=	NFfSVno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NVEyQSd-MkWwOVEyOTl:L3G+
HL-60	Ml3LSpVv[3Srb36gRZN{[Xl?	M1\FZ\|EvOCEQvF2=	NEDQSGI1QCCq		M1vCcIlv[3KnYYPld{BxOjGZQV[xM2NKWDIEoHHu[EBk[XOyYYPlMVMh\XiycnXzd4lwdsLi	NX7lTnptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVEyOTlpPkK1NFUyOTF7PD;hQi=>
HL-60	M3TybWZ2dmO2aX;uJGF{e2G7	NUPySWk1OS5yIN88US=>	NXfEd2RSPDhiaB?=		NXm1NYdk\GWlcnXhd4V{KEKlbD34UEBmgHC{ZYPzbY9vyqC\|aXfubYZq[2GwdHz5	M4HXN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWxNVE6Lz5{NUC1NVEyQTxxYU6=
HuTu-80	M2DXeWZ2dmO2aX;uJGF{e2G7	NFnJS5kyNzVxMUCg{txO	MmHrOFgwPzJiaB?=		NH;Qd3VqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhcHWvYX6gUnBEOUxzIH3SUmEhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M1fVWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC0NFYzLz5{NEmwOFA3OjxxYU6=
Caco2	NEDMd\|lHfW6ldHnvckBCe3OjeR?=	MYCxNEDPxE1?	NHLsUXk1QCCq		MVjpcoNz\WG\|ZYOgUnBEOUxzIHX4dJJme3Orb36=	M1;KPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC0NFYzLz5{NEmwOFA3OjxxYU6=
HepG2	M4D4c2Z2dmO2aX;uJGF{e2G7	NFLVdpkxNTJ3IN88US=>	NGWyeZEzPCCq		MlXu[IVkemWjc3XzJJN2[nSrbHnzbY4wc2W6aX6geJlx\SB7IDjQR3NMQSlicILveIVqdiCuZY\lcJMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NYnQe\|Z1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVU3PDZpPkK0PFU2PjR4PD;hQi=>
HepG2	MUTGeY5kfGmxbjDBd5NigQ>?	MlzQNE0zPSEQvF2=	NV\FUZdKOjRiaB?=		MnO4bY5kemWjc3XzJIxwfyCmZX7zbZR6KGyrcH;wdo91\WmwIILlZ4VxfG:{IDjMSGxTMSCpZX7lJIV5eHKnc4Ppc47DqA>?	NVnEU5RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVU3PDZpPkK0PFU2PjR4PD;hQi=>
HepG2	MkHYSpVv[3Srb36gRZN{[Xl?	M2LuUFExKM7:bdMg	NWW5eZJTOC1{NDDo		NVz2RlVU\GWlcnXhd4V{yqCSQ2PLPeKh[W6mwrDIUWdEWsLiZYjwdoV{e2mxbjDhcoQhcW6lcnXhd4V{KEyGTGKg[ZhxemW\|c3nvckBi\nSncjC2JIg>	NV\RR3VsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVU3PDZpPkK0PFU2PjR4PD;hQi=>
HepG2	NVLofXlzTnWwY4Tpc44hSXO\|YYm=	Ml\ENVAh\|ryv	MYiyOEBp		MVHwdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{	M{jG[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW1OlQ3Lz5{NEi1OVY1PjxxYU6=
HepG2	NVjiR5lNTnWwY4Tpc44hSXO\|YYm=	MXGxNEDPxG1?	MoHoNlQhcA>?		MkDkdJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?=	NXn5c2JQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVU3PDZpPkK0PFU2PjR4PD;hQi=>
HC45	MVjGeY5kfGmxbjDBd5NigQ>?	NFuzRXM2yrWPwrC=	NYHScHo2PCCm		MmXpdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF?	NUTtPG1SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlI5ODlpPkK0O\|YzQDB7PD;hQi=>
CNDT2	NWm1TZdnTnWwY4Tpc44hSXO\|YYm=	NET5dXU2yrWPwrC=	NVTuNpRyPCCm		MVPy[YR2[2W\|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN\|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>?	MkToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkK4NFkoRjJ2N{[yPFA6RC:jPh?=
CNDT2	M2fq[mZ2dmO2aX;uJGF{e2G7	NWWwN\|I4PcL3TdMg	NHXwd\|I1KGR?		MXvpcoNz\WG\|ZYOg[4Vv\SCneIDy[ZN{cW:wIH;mxsBYUUZzLDDQNVYtKEOGSEGsxsBNSU2DMT\|CpIFv\MLiQ2TOUmIy	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MkiwPUc,OjR5NkK4NFk9N2F-
T-cells	NVL2OGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoqyOU8zOCEQvF2=	NG\ZbocxNTR6IHi=		NHzCN5FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NGPmc249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD3+ T-cells	NFzHToJHfW6ldHnvckBCe3OjeR?=	M1jmV\|UwOjBizszN	MUC0PEBp		M2PnUpVxemWpdXzheIV{KHBzNTDlfJBz\XO\|aX;u	MkSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD4+ T-cells	M{m1ZmZ2dmO2aX;uJGF{e2G7	MljpOU8zOCEQvF2=	MVy0PEBp		Mn\oeZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36=	M1y3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD8+ T-cells	Mo\nSpVv[3Srb36gRZN{[Xl?	NXi0OXdiPS9{MDFOwG0>	NHTnOWE1QCCq		Mni4eZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36=	MlW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD3+ T-cells	MUnGeY5kfGmxbjDBd5NigQ>?	NXm3[mI4PS9{MDFOwG0>	MXm0PEBp		M1LCV5VxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKE[RWGCz	MofPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD4+ T-cells	MVvGeY5kfGmxbjDBd5NigQ>?	MWK1M\|IxKM7:TR?=	MVm0PEBp		NYLLVIZpfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM>	NFLCPXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells	NWjX[297TnWwY4Tpc44hSXO\|YYm=	M1L3O\|UwOjBizszN	NEW4Nmk1QCCq		NIfEVpRz\WS3Y3XzJHRDTVRzwrDtVm5CKGW6cILld5Nqd25?	MnS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD4+ T-cells	MV\GeY5kfGmxbjDBd5NigQ>?	NFqzeoQ2NzJyIN88US=>	NVv5N5dXPDhiaB?=		M3PkUJVxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nyqCUT2NOt5TDqA>?	M{\s[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD4+ T-cells	MoK2SpVv[3Srb36gRZN{[Xl?	MnvPOU8zOCEQvF2=	MYC0PEBp		M4m3XYlvcGmkaYTzJI1mdW:{eTDUMYNmdGy\|	NImwdXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD8+ T-cells	NV;vTG5FTnWwY4Tpc44hSXO\|YYm=	MmDDOU8zOCEQvF2=	NGHPR\|g1QCCq		M1;NNYlvcGmkaYTzJI1mdW:{eTDUMYNmdGy\|	M2PMRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD3+ T-cells	MXfGeY5kfGmxbjDBd5NigQ>?	NYTpcm15PSEQvF2=	MYq0PEBp		NXvxN\|lnemWmdXPld{Btd26pLYTldo0hdWWvb4L5JINmdGxicHjlco91gXCn	NWDPbmdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O\|U4Ojh\|PD;hQi=>
U937	NVX3NINDSXCxcITvd4l{KEG\|c3H5	M3nNblExKM7:TR?=	MYC3NkBp		MWfpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEC4OlUoRjJ2NkiwPFY2RC:jPh?=
HL-60	MYfBdI9xfG:\|aYOgRZN{[Xl?	NH7TSWgyOCEQvF2=	NUnhbnhpPzJiaB?=		NUPmOFlPcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	NVjjSnliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFA5PjVpPkK0OlgxQDZ3PD;hQi=>
MCF7	MoHtSpVv[3Srb36gRZN{[Xl?	MVq1JO69VQ>?	MmqzOFghcMLi		NEPNPY1lcXOybHH5d{B{\WynY4TpeoUhfG:6aXPpeJkhfG:5YYLkJJN2e3CnbnTl[EBOS0ZvNzDj[Yxtew>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|M{O1NEc,OjR4M{OzOVA9N2F-
MCF7	NF7meI5HfW6ldHnvckBCe3OjeR?=	Mo\BNVAh\|ryP	M{\5S\|I1KGkEoB?=		MnTNbY5lfWOnczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\SB5IHHu[EBRSVKSwrC=	NHTJe3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	MWrGeY5kfGmxbjDBd5NigQ>?	NFjBR5Qx6oDVMD61JO69VcLi	Mn\LO{Bl		NGLqXG5qdmirYnn0d{B1cGViZ4Lve5RpKE2FRj23JJR2dW:{c4Do[ZJmeyCrbjDzeZNx\W6\|aX;uJIN2dHS3cnXzxsA>	M3TNT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN\|UxLz5{NE[zN\|M2ODxxYU6=
MCF7	MXrGeY5kfGmxbjDBd5NigQ>?	NIO3e4UxNjVizszNxsA>	MV2xOEBl		MoPRdoVlfWOnczD0bIUhe2m8ZTDv[kBOS0ZvNzDjc4xwdmmnczDlcYJm\GSnZDDpckB{d2[2IHHnZZI>	Mn;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
MCF7	NGXUXYZHfW6ldHnvckBCe3OjeR?=	MUewMlA26oDVMkCg{txO	M33FbFEh\A>?		MWry[YR2[2W\|IITo[UBkdG:wYXygd5Vzfmm4YXygc4YhVUOILUegZ4VtdHNiaX6gcY9vd2yjeXXyJIN2dHS3cnXz	NFrITIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
T47D	MnvKSpVv[3Srb36gRZN{[Xl?	M37ocFAvPSEQvF2=	MmDEOEBl		M3TXdYlvcGmkaYTzJJR2dW:{c4Do[ZJmKG[xcn3heIlwdg>?	M1W1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN\|UxLz5{NE[zN\|M2ODxxYU6=
MCF7	MnTaSpVv[3Srb36gRZN{[Xl?	NXmzW2RSOC534pETNVAh\|ryP	MkLGOFghcMLi		MUnpcohq[mm2czD0bIUh\2GyIHPsc5N2emViaX6geIhmKHexdX7kJIhm[WyrbnegZZN{[Xl?	NGfTfGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	NWO2XmdbTnWwY4Tpc44hSXO\|YYm=	NHK1cm4xNzFyIN88US=>	NWXtZZkyOjRiaB?=		M1e4OolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXA6	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|M{O1NEc,OjR4M{OzOVA9N2F-
MDA-MB-231	MWTGeY5kfGmxbjDBd5NigQ>?	NGW1dmgxNjYkgKOxNEDPxE1?	MWezOkBp		MXTpcohq[mm2czD0bIUhdWmpcnH0bY9v	MmjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
SKM1-S	NXT0b5VuSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIPtPGw1QCCqcoO=		NV;ab4cySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT20yNVNiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFAvPSEQvF2u	NIjoN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC5OFk{QCd-MkiwPVQ6Ozh:L3G+
SKM1-S	NXXxUYllSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn;MOFghcHK\|		MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONTUGtV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliRFHQTU1{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNibXX0bI9lNCCHQ{WwJF0hOC53MTFOwG0v	MkXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyOUS5N\|goRjJ6MEm0PVM5RC:jPh?=
A427	M1fOVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3jOPVk3KGi{cx?=		MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2MkegZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KGO{eYP0ZYwhfmmxbHX0JIF{e2G7LDDJR\|UxKD1iMD62N{DPxE1w	NEX3OHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE3Oyd-MUi0N\|QyPjN:L3G+
KYSE70	NYSx[oRuSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1TjbVk3KGi{cx?=		NGfDN3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvZV2U4OCClZXzsd{Bi\nSncjC5OkBpenNiYomgZ5J6e3SjbDD2bY9t\XRiYYPzZZktKEmFNUCgQUAyNjV7IN88UU4>	M1;PelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEO0NVY{Lz5zOESzOFE3OzxxYU6=
5637	M1q2RmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NULHe\|RPQTZiaILz		M13lWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iNU[zO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliY4L5d5RidCC4aX;s[ZQh[XO\|YYmsJGlEPTBiPTCxMlc{KM7:TT6=	M4XtNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEO0NVY{Lz5zOESzOFE3OzxxYU6=
HT-29	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGLZS\|g6PiCqcoO=		NH\VNGtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzMlgh\|ryPLh?=	MlzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5OES0PUc,Ojd5OES0PVww[T5?
P388	NFvOO4lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXG4R3VpPDhiaILz		M3LQSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUEO4PEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNTFOwG0v	NWewWZZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3PFQ1QSd-Mke3PFQ1QTxxYU6=
MCF7	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFTjSIc6PiCqcoO=		M3rzcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliY4L5d5RidCC4aX;s[ZQh[XO\|YYmsJGlEPTBiPTC2Mlc5KM7:TT6=	MoK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2M{SxOlMoRjF6NEO0NVY{RC:jPh?=
U373-MAGI	M1K0b2FvfGm4aYLhcEBie3OjeR?=	M{f1b\|I2KHSxIESwNEB2VQ>?	NHy2NnQzKHSxIEeyJIhzew>?		NUDrPFlESW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBo[WdibHX2[Ywh[XRiMkWgeI8hPDByIIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m	NIfVV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
U373-MAGI	M{\oPWFvfGm4aYLhcEBie3OjeR?=	Ml;uNlUhfG9iNECwJJVO	NFH4SoQzKHSxIEeyJIhzew>?		MVzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDWV3YuTyCyc3X1[I91gXCnZDDITXYuOSCQTEStN{Bqdm[nY4Tl[EBqdiCqdX3hckBWOzd\|LV3BS2kh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIGW1MYdi\yCuZY\lcEBifCB{NTD0c{A1ODBidV2gZYZ1\XJiMjD0c{A4OiCqcoOgZpkheVCFUjDt[ZRpd2R?	M3zxfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
L1210	MlvhR5l1d3SxeHnjbZR6KGG\|c3H5				M1rVV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGwyOjFyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPld5NifGmxbjDv[kBoem:5dHi=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek83QTB{Nje+OlkxOjZ:L3G+
TC32	M{m3b5FJXFNiYYPzZZk>				MnHYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	NV:zcHJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	Mn61dWhVWyCjc4PhfS=>				MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MVPxTHRUKGG\|c3H5				NULZeJY2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	Mn;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NVLhT4NDeUiWUzDhd5NigQ>?				MmTqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M4CwPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	Mkj6dWhVWyCjc4PhfS=>				NHL4UJNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	NIL5bI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MlvJdWhVWyCjc4PhfS=>				NUi4XphVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MX;xTHRUKGG\|c3H5				M2PYNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NW\meZlWeUiWUzDhd5NigQ>?				M3X4cZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M3zqXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SKM1-S	M{i1cGFxd3C2b4Ppd{Bie3OjeR?=	M3P1[\|EhfU1?			MoXGTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS12xMXMh[2WubIOgZZN{\XO\|ZXSgZZMh[2G\|cHHz[UA{KGOuZXH2ZYdmKGG2IEGgeW0h[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	NXz0dYJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwPVQ6OzhpPkK4NFk1QTN6PD;hQi=>
MCF7	MUjGeY5kfGmxbjDhd5NigQ>?	MoOzNVUhfU1?	M4jEc\|czKGi{cx?=		MlfuTY5pcWKrdHnvckBw\iCXSGLGNUBqdiCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJI1mfGi7bHH0bY9vKGG2IGLBVkBj\XSjIHX4c44h[XRiMUWgeW0h[W[2ZYKgO\|IhcHK\|IHL5JI1mfGi7bHH0bY9vKHOyZXPp[olkNVCFUjDt[ZRpd2R?	MknsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNEm1O\|coRjJ5MES5OVc4RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control. c-PARP / p-H2AX / H2AX; PubMed: 28210112 Lung Cancer (Auckl) AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘	28210112
Immunofluorescence	HMGB1 ; PubMed: 29097772 Sci Rep U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemｾ᎒	29097772
Growth inhibition assay	Cell viability ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖	28210112

In vivo

Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]

Protocol

Cell Research:^[3]	- Collapse Cell lines: Leukemia L1210 cell Concentrations: 0.15 μg/mL Incubation Time: 3 days Method: 5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: BDF1 mice bearing lymphoid leukemia L1210 Dosages: 3 mg/kg Administration: Daily i.p. injection (Only for Reference)

References

[4] Heby O, et al. Cancer Res. 1973, 33(1), 159-165.

- Collapse

Solubility (25°C)

In vitro	DMSO	48 mg/mL warmed (196.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Azacitidine (5-Azacytidine) SDF

Molecular Weight	244.2
Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	5-AzaC,Ladakamycin, AZA,5-Aza, CC-486
Smiles	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04638309	Recruiting	Drug: APR-548 + Azacitidine	MDS\|Myelodysplastic Syndromes	Aprea Therapeutics	April 2021	Phase 1
NCT04806906	Recruiting	Drug: CC-486	MDS\|CMML	University of Florence	March 2021	Phase 2
NCT04742101	Recruiting	Drug: S65487 and azacitidine	Acute Myeloid Leukemia	Institut de Recherches Internationales Servier\|ADIR a Servier Group company\|Servier	March 10 2021	Phase 1\|Phase 2
NCT04629443	Not yet recruiting	Drug: S 64315 (also referred as MIK665) and azacitidine	Acute Myeloid Leukaemia	Institut de Recherches Internationales Servier\|ADIR a Servier Group company\|Servier	November 16 2020	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?
Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Choose Your Country or Region

By Signaling Pathways

By product type

Azacitidine (5-Azacytidine)